Date Title
November 17, 2017
Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director and Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the Board
MALVERN, Pa., Nov. 17, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Sanford (Sandy) Zweifach has been appointed to the Company's board as a
November 2, 2017
Realm Therapeutics to Present at BIO-Europe® 2017
MALVERN, Pa., Nov. 2, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 23 rd annual BIO-Europe ® , a global
October 30, 2017
Realm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of Allergy, Asthma, and Immunology (ACAAI) Scientific Meeting
MALVERN, Pa. , Oct. 30, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the Company presented data for PR013 at the American College of Allergy, Asthma, and
Displaying 41 - 43 of 43

Search Investor Relations